Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 -1.88%74 Interest Coverage is 767.64 as of Dec. 2025, which is 80% above its 10-year median of 426.94. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 90.32% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Diva Laboratories's
Operating Income
for the
three
months ended in Dec. 2025 was NT$33.8 Mil. Diva Laboratories's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0.0 Mil.
Diva Laboratories's interest coverage for the quarter that ended in Dec. 2025 was 767.64.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Diva Laboratories Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Diva Laboratories's Interest Coverage or its related term are showing as below:
ROCO:4153'
s Interest Coverage Range Over the Past 10 Years
Min: 5.89 Med: 426.94 Max: 65770
Current: 455.68
ROCO:4153's Interest Coverage is ranked better than 90.32% of 93
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs ROCO:4153: 455.68
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Diva Laboratories Interest Coverage Related Terms
Diva Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:4153 vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories (ROCO:4153) has a Interest Coverage of 767.64 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Diva Laboratories and its competitors. This is 80% above median its historical median of 426.94. Over the past decade, Diva Laboratories' Interest Coverage has ranged from 5.89 to 65,770.00. According to the industry distribution chart, Diva Laboratories ranks #9 out of 93 companies in the Medical Diagnostics & Research industry, placing it in the top 9.7%.
Is Diva Laboratories' Interest Coverage too high?
Diva Laboratories' current Interest Coverage of 767.64 is 80% above median its 10-year median of 426.94. Over the past 10 years, this metric has ranged from a low of 5.89 to a high of 65,770.00. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. Diva Laboratories' value of 767.64 is 8382.2% above this industry median. Based on the distribution chart, Diva Laboratories ranks #9 out of 93 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #9 out of 93 companies for Interest Coverage. This places Diva Laboratories in the top 10% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 9.05. Diva Laboratories' value of 767.64 is 8382.2% above this benchmark. Historically, Diva Laboratories' own Interest Coverage has ranged from 5.89 to 65,770.00 over the past decade. While the company's 10-year median is 426.94 vs. the industry median of 9.05, Diva Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current Interest Coverage of 767.64 is 8382.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current Interest Coverage is 767.64, which is 80% above median its own 10-year median of 426.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.40 — trading 17.4% below its estimated fair value. The current Interest Coverage is 767.64, which is 80% above median its 10-year median of 426.94 and 8382.2% above the Medical Diagnostics & Research industry median of 9.05. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current Interest Coverage is 767.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.40 is trading 17.4% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
Interest Coverage: 767.64 (80% above median its 10-year median of 426.94)
GF Value™: NT$38.03 vs. price of NT$31.40 (17.4% below fair value)
Industry Position: 8382.2% above the Medical Diagnostics & Research median (#9 of 93)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
